|
4 Companies |
|
2 Products |
|
2 Products |
|
3 Mechanisms of Action |
|
0 Trials |
|
8 News |
|
- | Ilaris (canakinumab) / Novartis
Trial completion: Ilaris (clinicaltrials.gov) - Jul 17, 2018
P2, N=20, Completed, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed
- Ilaris (canakinumab) / Novartis
Trial primary completion date: Ilaris (clinicaltrials.gov) - Mar 3, 2018
P2, N=20, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed Trial primary completion date: Jan 2018 --> Dec 2017
- | Trial completion, Enrollment change, Trial primary completion date: Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors (clinicaltrials.gov) - Sep 8, 2017
P=N/A, N=52, Completed, Sponsor: University Hospital, Strasbourg, France
Trial primary completion date: Jan 2018 --> Dec 2017 Recruiting --> Completed | N=70 --> 52 | Trial primary completion date: Mar 2014 --> Sep 2017
- Ilaris (canakinumab) / Novartis
Trial primary completion date: Ilaris (clinicaltrials.gov) - Feb 5, 2015
P2, N=20, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | N=70 --> 52 | Trial primary completion date: Mar 2014 --> Sep 2017 Trial primary completion date: Sep 2016 --> Jan 2018
- Ilaris (canakinumab) / Novartis
Trial primary completion date: Ilaris (clinicaltrials.gov) - Jun 17, 2014
P2, N=20, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Sep 2016 --> Jan 2018 Trial primary completion date: Dec 2013 --> Sep 2016
- | Ilaris (canakinumab) / Novartis
Enrollment closed: Ilaris (clinicaltrials.gov) - Oct 16, 2012
P2, N=20, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Dec 2013 --> Sep 2016 Recruiting --> Active, not recruiting
- Ilaris (canakinumab) / Novartis
Enrollment change: Efficacy and Safety of Canakinumab in Schnitzler Syndrome (clinicaltrials.gov) - May 22, 2012
P2, N=8, Completed, Sponsor: Radboud University
Recruiting --> Active, not recruiting N=10 --> 8
- Ilaris (canakinumab) / Novartis
Trial completion: Efficacy and Safety of Canakinumab in Schnitzler Syndrome (clinicaltrials.gov) - May 22, 2012
P2, N=8, Completed, Sponsor: Radboud University
N=10 --> 8 Active, not recruiting --> Completed